DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Acitretin Plasma Levels Under Hemodialysis

Information source: University of Zurich
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Carcinoma, Squamous Cell

Intervention: Chemopreventive application (Acitretin) (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of Zurich

Official(s) and/or principal investigator(s):
01 Studienregister MasterAdmins, Study Director, Affiliation: UniversitaetsSpital Zuerich

Overall contact:
01 Studienregister MasterAdmins, Phone: +41 (0)44 255 11 11

Summary

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.

Clinical Details

Official title: Acitretin Plasma Levels Under Hemodialysis

Study design: Allocation: Non-Randomized, Control: Historical Control, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Plasma levels acitretin

Detailed description: Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined.

- Trial with medicinal product

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion criteria:

- Hemodialyis patients with at least one case of in-situ or invasive squamous cell

carcinoma of the skin

Exclusion criteria:

- Hepatopathy

- Pregnancy

Locations and Contacts

01 Studienregister MasterAdmins, Phone: +41 (0)44 255 11 11

Clinic for Dermatology University Hospital of Zurich, Zurich, Switzerland; Recruiting
Günther Hofbauer, MD, Email: hofbauer@usz.ch
günther Hofbauer, MD, Principal Investigator
Additional Information

Starting date: June 2007
Last updated: January 11, 2010

Page last updated: October 04, 2010

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012